2026 ACC/AHA Dyslipidemia Guidelines: Lower LDL, Starting Earlier in Life

 What's new at a glance

The updated guidelines replace the longstanding Pooled Cohort Equations (PCE) with the PREVENT risk calculator, reinstate specific LDL cholesterol targets absent since 2013, and emphasize 30-year lifetime ASCVD risk rather than 10-year snapshots alone. Several newly FDA-approved agents — bempedoic acid, inclisiran, and evinacumab — are incorporated into the treatment landscape.

The case for treating earlier

A central theme is reducing lifelong exposure to atherogenic lipoproteins by intervening earlier. Once arterial plaque develops, it cannot be reversed — making prevention before disease onset the priority.

Statin therapy is now recommended earlier for:

• All adults with heterozygous familial hypercholesterolemia (FH)
• Adults ≤30 years old with LDL ≥ 160 mg/dL
• Those with a strong family history of ASCVD
• Those with high 30-year ASCVD risk on the PREVENT calculator

The ideal LDL cholesterol goal for primary prevention is ≤ 100 mg/dL, supported by lifestyle optimization and pharmacotherapy when needed.

Primary prevention: risk-stratified targets

The PREVENT calculator defines four risk tiers, each with clear guidance:

• Low risk (<3% 10-year) with LDL 160–189 mg/dL or 30-year risk ≥10%: moderate-intensity statin is reasonable (Class 2a)
• Borderline risk (3–<5%): LDL target <100 mg/dL; moderate-intensity statin based on shared decision-making (Class 2a)
• Intermediate risk (5–<10%): moderate- or high-intensity statin per clinical judgment (Class 1)
• High risk (>10% 10-year): LDL target <70 mg/dL; high-intensity statin for ≥50% LDL reduction (Class 1)

Recommending treatment even for borderline-risk patients with LDL near 160 mg/dL represents a significant shift from prior guidelines.

Lipoprotein(a) and coronary artery calcium: stronger roles

Lp(a) measurement is now a Class 1 recommendation — once in every adult's lifetime. An elevated level (≥ 50 mg/dL) triggers intensified LDL lowering and broader risk factor management.

Coronary artery calcium (CAC) scoring serves as the premier "tiebreaker" when treatment decisions are uncertain:

• CAC = 0: Consider deferring therapy
• CAC 1–999 AU: Treat to LDL <70 mg/dL and non-HDL <100 mg/dL (Class 1)
• CAC ≥ 1,000 AU: Target LDL <55 mg/dL with ≥50% LDL reduction (Class 1)

ApoB testing and the CPR model

Apolipoprotein B (apoB) testing now has a clear pathway (Class 2a) for further risk stratification once LDL and non-HDL goals are met, particularly in patients with elevated triglycerides, diabetes, or cardiovascular-kidney-metabolic (CKM) syndrome.

The guidelines encourage a "CPR" framework: Calculate 10- and 30-year risk, Personalize using risk enhancers and biomarkers, then Reclassify and Reassess over time.

Secondary prevention: tighter targets for very-high-risk patients

For patients with established ASCVD at very high risk — two or more major ASCVD events, or one event plus two additional high-risk conditions — goals are now:

• LDL <55 mg/dL and non-HDL <85 mg/dL

To achieve these targets, ezetimibe and/or a PCSK9 inhibitor should be added to maximally tolerated statin therapy (Class 2a). Inclisiran is a reasonable alternative for patients who cannot tolerate or prefer less-frequent dosing (Class 2a).

Risk enhancers and special populations

Multiple risk enhancers can influence treatment in borderline or intermediate-risk patients, including family history, high-risk ancestry (South Asian, Filipino), elevated high-sensitivity CRP, elevated triglycerides, and presence of inflammatory diseases or CKM syndrome.

Additional guidance covers:

• Chronic kidney disease (stages 3–4): LDL <55 mg/dL target — Class 1 recommendation
• HIV patients (ages 40–75) on stable antiretroviral therapy: statins recommended (Class 1)
• Diabetes without ASCVD: statin therapy recommended (Class 1)
• Hypertriglyceridemia: lifestyle-first — ≥5% weight loss and ≥150 min/week moderate exercise
• Pregnancy and lactation: nuanced shared discussion replacing a blanket statin stop; dietician referral encouraged

Bottom line: The 2026 ACC/AHA guidelines return LDL targets, extend the treatment window to younger adults, elevate Lp(a) and CAC scoring as key decision-making tools, and align US recommendations more closely with European standards. The overarching message: lower cholesterol, for longer, starting sooner.